Frederik Alexander Stuebs

Dr. Frederik Alexander Stuebs

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2018 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
FSFrederik Alexander Stuebs
Frederik Alexander Stuebs
CSCarla E. Schulmeyer
Carla E. Schulmeyer
GMGrit Mehlhorn
Grit Mehlhorn
PGPaul Gass
Paul Gass
SKSven Kehl
Sven Kehl
MKMartin C. Koch
Martin C. Koch

4 February 2021 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
FSFrederik Alexander Stuebs
Frederik Alexander Stuebs
PGPaul Gass
Paul Gass
ADAnna K. Dietl
Anna K. Dietl
CSCarla E. Schulmeyer
Carla E. Schulmeyer
WAWerner Adler
Werner Adler
MKMartin C. Koch
Martin C. Koch

9 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DFDaniel Firmbach
Daniel Firmbach
MBMichaela Benz
Michaela Benz
PKPetr Kuritcyn
Petr Kuritcyn
VBVolker Bruns
Volker Bruns
CLCorinna Lang-Schwarz
Corinna Lang-Schwarz
Carol GeppertCarol Geppert
Carol Geppert
The tumor–stroma ratio (TSR) has been repeatedly shown to be a prognostic factor for survival prediction of different cancer types. However, an objective and reliable determination of the tumor–stroma ratio remains challenging. We present an easily adaptable deep learning model for accurately segmenting tumor regions in hematoxylin and eosin (H&E)-stained whole slide images (WSIs) of colon cancer patients into five distinct classes (tumor, stroma, necrosis, mucus, and background). The tumor–stroma ratio can be determined in the presence of necrotic or mucinous areas. We employ a few-shot model, eventually aiming for the easy adaptability of our approach to related segmentation tasks or other primaries, and compare the results to a well-established state-of-the art approach (U-Net). Both models achieve similar results with an overall accuracy of 86.5% and 86.7%, respectively, indicating that the adaptability does not lead to a significant decrease in accuracy. Moreover, we comprehensively compare with TSR estimates of human observers and examine in detail discrepancies and inter-rater reliability. Adding a second survey for segmentation quality on top of a first survey for TSR estimation, we found that TSR estimations of human observers are not as reliable a ground truth as previously thought.

28 January 2020 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
FSFrederik Alexander Stuebs
Frederik Alexander Stuebs
MKMartin C. Koch
Martin C. Koch
GMGrit Mehlhorn
Grit Mehlhorn
PGPaul Gass
Paul Gass
CSCarla E. Schulmeyer
Carla E. Schulmeyer
SRSimone K. Renner
Simone K. Renner

19 July 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
FSFrederik Alexander Stuebs
Frederik Alexander Stuebs
MKMartin C. Koch
Martin C. Koch
ADAnna K. Dietl
Anna K. Dietl
WAWerner Adler
Werner Adler
Carol GeppertCarol Geppert
Carol Geppert
PGPaul Gass
Paul Gass
Background: A new nationwide screening strategy was implemented in Germany in January 2020. No data are available for women referred to certified dysplasia units for secondary clarification after primary diagnosis by a local physician. We therefore investigated combined testing with Papanicolaou smears and high-risk human papillomavirus (hrHPV) and compared the data with the final histological findings. Methods: Between January 2015 and October 2020, all referred women who underwent colposcopy of the uterine cervix in our certified dysplasia unit were included. Cytology findings were classified using the Munich III nomenclature. Results: A total of 3588 colposcopies were performed in 3118 women, along with Pap smear and hrHPV co-testing, followed by histology. Women with Pap II-p (ASC-US) and a positive hrHPV co-test had a 22.4% risk for cervical intraepithelial neoplasia (CIN) 3/high-grade squamous intraepithelial lesion (HSIL). The risk of CIN 3/HSIL was 83.8% in women with Pap IVa-p (HSIL) and a positive hrHPV co-test. A positive hrHPV co-test increased the risk for HSIL+ (OR 5.942; 95% CI, 4.617 to 7.649; p < 0.001) as compared to a negative hrHPV co-test. Conclusions: The accuracy of Pap smears is comparable with the screening results. A positive hrHPV test increases the risk for HSIL+ fivefold. Colposcopy is necessary to diagnose HSIL+ correctly.

8 October 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
FSFrederik Alexander Stuebs
Frederik Alexander Stuebs
ADAnna K. Dietl
Anna K. Dietl
ABAnnika Behrens
Annika Behrens
WAWerner Adler
Werner Adler
Carol GeppertCarol Geppert
Carol Geppert
MKMartin C. Koch
Martin C. Koch
Background: The purpose of this research is to estimate the rate of concordance, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of colposcopy for high-grade squamous lesions and carcinomas (HSIL+). Methods: We conducted a retrospective study of colposcopies performed in the certified Dysplasia Unit in Erlangen between January 2015 and May 2022 (7.5 years). The colposcopic findings were correlated with biopsies obtained during examinations or surgery. Cases without histology were excluded. The primary outcome was the rate of concordance between the colposcopic and histological findings in relation to the type of transformation zone (TZ), examiner’s level of experience and age of the patients. Results: A total of 4778 colposcopies in 4001 women were analyzed. The rates of concordance for CIN I/LSIL, CIN II/HSIL, CIN III/HSIL, and carcinoma were 43.4%, 59.5%, 78.5%, and 53.9%, respectively. The rate of concordance was lowest for TZ3 and highest for colposcopists with more than 10 years’ experience. Conclusions: Colposcopy is an important, feasible, and effective method. Careful work-up needs to be performed for women with TZ3 who are over 35 years old, as they are at the highest risk of being misdiagnosed. The highest concordance for detecting HSIL+ was seen for colposcopists with >10 years’ experience.